Target
$90.83 → $90.50
Current stock research snapshot · 7/31/26 26 days old
EWEdwards Lifesciences
Investment conviction●●○○○2 of 5 · current snapshot
Research target$90.50Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed 7/31/26
Market cap$49.38BSnapshot value · 7/31/26
Research history
See all EW changes ↗What changed
Target
$90.85 → $90.83
Healthspan taxonomy seed — see taxonomy_path
Edwards Lifesciences Q2 2026 earnings; TAVR procedure volume recovery; PASCAL (mitral) adoption trend
Thesis breaks if 10-yr PARTNER 3 durability data (2028-29) shows SVD >10% converging with surgical valves, or CMS NCD restricts TAVR eligibility cutting procedure growth from 8-10% to 3%. (vault 2026-08)
Neutral — No significant X discussion found in the last 30 days. [X search Aug 2026]
Snapshot · 7/31/26🟡 Mixed · ins-$7.8M · 13F 14+/11-×0.5 · short↓0.21
Snapshot · 7/31/26Timestamped research update
Deep research update
760 words · Updated Aug 2, 2026
Research in development: this latest 760-word update is published for context while it is expanded toward the 1,000-word editorial standard.
Edwards Lifesciences is the global leader in transcatheter structural heart devices — primarily the SAPIEN platform for transcatheter aortic valve replacement (TAVR) plus an expanding mitral/tricuspid (TMTT) franchise including PASCAL, EVOQUE, and SAPIEN M3. Post-Critical Care divestiture (Sep 2024), EW is a pure-play structural heart company.
FY2025 continuing-ops revenue $5.01B, gross margin 80.4%, operating margin 26.1%. FY2026 guided to $6.6B-$6.9B (+32-38% reported, +10-11% organic CC). Net income $1.40B FY2025. Balance sheet: $10.0B equity, $2.99B liabilities — effectively zero net debt. R&D at 19.2% of revenue reflects clinical trial intensity.
EW is the definitive "picks-and-shovels" play on the structural heart intervention wave — it controls the SAPIEN platform whose 20-year PARTNER clinical trial dataset creates an FDA-validated safety/durability record competitors cannot replicate without running decade-scale trials. The switching cost is hospital-operational: surgeon retraining, imaging protocol recalibration, inventory conversion — ~$475K-$900K per center. Combined with RESILIA tissue treatment's anti-calcification durability advantage over Medtronic's AOA-treated tissue, EW sits on a three-layer regulatory/clinical/operational moat that compounds with every additional PARTNER data release and every new PMA indication expansion.
- Q2 2026 TAVR revenue $1.26B (+11.3% reported, +10.5% CC) — accelerating from the 8-9% guided full-year rate. Source: 2026-07-23 EX-99.1
- FY2026 guidance raised: total CC growth 10-11% (from 9-11%), TAVR CC growth 8-9% (from 7-9%), TMTT $760M-$780M (from $740M-$780M). Source: EX-99.1
- Competitor exited certain geographies in Q2 2025, expanding Edwards' window. Likely Medtronic CoreValve/Evolut withdrawal. Source: Q2 2026 earnings release language
- SAPIEN 3 Ultra RESILIA platform driving adoption in US — PARTNER 3 sub-analysis at New York Valves 2026 confirmed best-in-class durability vs. competitor tissue treatments
- CMS reconsidering NCD for TAVR — final decision memo pending, could expand or restrict TAVR eligibility
- TMTT portfolio expanding: EVOQUE tricuspid replacement (first-mover in $3B+ TAM), SAPIEN M3 mitral replacement (transfemoral), PASCAL Precision mitral repair
- 20-year PARTNER trial program (>15,000 patients across all risk categories) is the largest TAVR evidence base — no competitor has equivalent data depth
- Balance sheet fortress: $10.0B equity, $2.99B liabilities, R&D at 19.2% of revenue funding clinical pipeline
Three-layer moat: (1) Regulatory-clinical — PARTNER trial program is 20 years deep, 15K+ patients, FDA PMA across all risk categories; a new entrant needs decade-scale trials. (2) Tissue technology — RESILIA anti-calcification treatment demonstrates superior 5-8 year durability vs. Medtronic's AOA-treated porcine tissue. (3) Hospital operational switching cost — $475K-$900K per center in retraining, imaging recalibration, inventory conversion, plus an embedded outcome risk premium from abandoning a proven platform. The switching cost alone equals 2-4× the annual device margin difference, making price competition irrational for hospitals.
- CMS NCD reconsideration could restrict TAVR eligibility if the final memo imposes tighter surgical-risk thresholds or mandatory heart-team concurrence requirements beyond current practice
- Polymer valve disruption (Foldax Tria) — a synthetic valve with indefinite durability would render tissue-treatment moats obsolete; still Phase 1/2, but the technology risk is real at a 5-10 year horizon
- TMTT clinical failure — EVOQUE or SAPIEN M3 pivotal data showing non-inferiority or inferiority to medical management would cap the terminal growth rate by removing ~25% of projected 2030 revenue
- BSX ACURATE neo2 US approval (~2027-2028) introduces a second major competitor in the US TAVR market; pricing pressure could compress gross margins from 78-80% toward 70-72%
- 10-year PARTNER 3 durability data (expected ~2028-2029) — if structural valve deterioration rates converge with surgical bioprosthetic valves at 10-year follow-up, the RESILIA durability moat collapses
- What does the CMS NCD final decision memo say, and what is the quantifiable TAVR procedure volume impact?
- Will EVOQUE tricuspid pivotal data show superiority to medical management, and at what magnitude?
- How much of the FY2026 $6.6B-$6.9B guidance is organic CC growth vs. acquisition contribution?
- At what pace does Boston Scientific's ACURATE neo2 roll out in the US, and what is the initial pricing strategy?
- Can the tissue engineering moat survive a polymer-valve competitor with proven 10+ year durability?
STRENGTHENED — competitor exit, accelerating TAVR growth (11.3% Q2 vs. 8-9% guided), raised guidance across all segments, and RESILIA's durability data lead combine to widen the moat. The three-layer regulatory/clinical/operational switching cost barrier is growing, not shrinking. The primary risk is a 5-10 year polymer-valve disruption, but in the 2-5 year investable window, Edwards' position is strengthening.